NKR 29. PICO 6: Psykoterapi ved kronisk og svært behandlelig depression

Review information

Authors

Sundhedsstyrelsen (Danish Health Agency)¹

Citation example: S(HA. NKR 29. PICO 6: Psykoterapi ved kronisk og svært behandlelig depression. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

Characteristics of studies

Characteristics of included studies

Agosti 1997

Methods	Study design: Randomized controlled trial Study grouping: Parallel group Open Label: Cluster RCT:
Participants	Baseline Characteristics Psychotherapy Treatment as Usual Included criteria: Excluded criteria: Pretreatment:
Interventions	Intervention Characteristics Psychotherapy • Beskrivelse: Interpersonel psykoterapi Treatment as Usual • Beskrivelse: Placebo Case Management
Outcomes	Frafald/All cause discontinuation Outcome type: DichotomousOutcome Reporting: Fully reported Direction: Lower is better Data value: Endpoint Hospitalsindlæggelser Outcome type: DichotomousOutcome
	 Reporting: Fully reported Direction: Lower is better Data value: Endpoint Hospitalsindlæggelser Outcome type: ContinuousOutcome Reporting: Fully reported

¹[Empty affiliation]

Direction: Lower is betterData value: Endpoint

Selvmordsadfærd

• Outcome type: DichotomousOutcome

Direction: Lower is betterData value: Endpoint

Arbejdsfastholdelse

• Outcome type: DichotomousOutcome

Reporting: Fully reportedDirection: Higher is betterData value: Endpoint

Skadevirkninger (farmakologisk)

Outcome type: AdverseEvent
Reporting: Fully reported
Direction: Lower is better
Data value: Endpoint

Funktionsevne (aktivitet og deltagelse)

• Outcome type: ContinuousOutcome

Reporting: Fully reported
Direction: Higher is better
Data value: Endpoint

Remissionsrate (kritisk outcome)

• Outcome type: DichotomousOutcome

Reporting: Fully reported
Direction: Higher is better
Data value: Endpoint

Livskvalitet (kritisk outcome)

• Outcome type: ContinuousOutcome

Reporting: Fully reported
Direction: Higher is better
Data value: Endpoint

Ham-d (respons rate), IPT

• Outcome type: DichotomousOutcome

Reporting: Fully reportedDirection: Higher is betterData value: Endpoint

BDI (respons rate), IPT

• Outcome type: DichotomousOutcome

Reporting: Fully reported
Direction: Higher is better
Data value: Endpoint

Ham-d (respons rate), CBT

• Outcome type: DichotomousOutcome

Direction: Higher is betterData value: Endpoint

	BDI (respons rate), CBT
	Outcome type: DichotomousOutcome
	Direction: Higher is better
	Data value: Endpoint
Identification	Sponsorship source: No information
	Country: USA
	Setting:
	Comments: No information on funding.
	Authors name: Agostia & Ocepek-Weliksona, 1997
	Institution:
	Email:
	Address: The Department of Psychiatry, Columbia University, New York,, USA
Notes	Birgitte Holm Petersen on 29/09/2015 07:33
	Select
	Sammenlign ml. mono psykoterapi og farmakologisk beh alene kan uddrages at
	arbejdet. Men, "Forty percent (26/65) met criteria for Intermittent Depression" =
	eksklusionsgrund.
	Stine MøLler on 13/10/2015 20:34
	Population
	earlyearly-onset chronic depression as an episode of Major Depression beginning
	before age twenty-oneDepression found that duration of depression ac- and
	lasting longer than two years.
	0//n = Mal / = n = n 40/40/0045 00:00
	Stine MøLler on 13/10/2015 20:36
	Interventions
	Imipraminepatients with and without early-onset chronic depres-Clinical Management (ICM), Cognitive Behaviorsion (N5204). Predictor variables were
	entered inTherapy (CBT) and Interpersonal Psychotherapythe following steps:
	(1) Baseline depression score;(IPT), with Placebo Case Management (PCM)
	(1) Bassing depression score, (ii 1), with hacebo case management (i civi)
	Stine MøLler on 13/10/2015 20:45
	Interventions
	IPT results were slighty poorer than CBT

Risk of bias table

Bias	Authors' judgement	Support for judgement
Sequence Generation	Unclear risk	Not described
Allocation concealment	Unclear risk	Not described
Blinding of participants and personnel	High risk	Not possible
Blinding of outcome assessors	High risk	Not possible
Incomplete outcome data	Low risk	Not detected

Selective outcome reporting	~	Not detMany rating scales are described in the 1985 protocol that turn out not to be reported.	
Other sources of bias	High risk	1-2 week washout phase for psychotropic drugs prior to baseline.	

Keller 2000

Methods	Study design: Randomized controlled trial Study grouping: Parallel group Open Label: Cluster RCT:
Participants	Baseline Characteristics Psychotherapy Treatment as Usual Included criteria: between the ages of 18 and 75 years; score of at least 20 on the 24-item Hamilton Rating Scale for Depression (HRSD) atscreening and, after a two-week drug-free period, at base line. Continuous illness of at least two years Excluded criteria: history of seizures, abnormal findings on electroencephalography,severe head trauma, or stroke; evidence suggestingthey were at high risk for suicide; a history of psychotic symptomsor schizophrenia; bipolar disorder, an eating disorder (if ithad not been in remission for at least one year), obsessive-compulsivedisorder, or dementia; antisocial, schizotypal, or severeborderline personality disorder; a principal diagnosis of panic, generalizedanxiety, social phobia, or post-traumatic stress disorders orany substance-related abuse or dependence disorder (except thoseinvolving nicotine) within six months before the study began; absenceof a response to a previous adequate trial of nefazodone ora cognitive behavioral-analysis system of psychotherapy; absenceof a response to three previous adequate trials of at least two differentclasses of antidepressants or electroconvulsive therapy or totwo previous adequate trials of empirical psychotherapy in thethree years preceding the study; a serious, unstable medical condition; or a positive urine screen for drugs of abuse. Women ofchildbearing potential had to agree to use adequate contraceptionduring the study. Patients were not allowed to take anxiolyticagents, sedatives, hypnotic agents, or any other types of sleep aids(pharmacologic or behavioral) during the study. Pretreatment:
Interventions	Intervention Characteristics Psychotherapy • Beskrivelse: The cognitive behavioral-analysis system of psychotherapy also followed a manual specifying twice-weekly sessions during weeks 1 through 4 and weekly sessions during weeks 5 through 12. Twice-weekly sessions could be extended until week 8 if a patient wasnot adequately performing a learned social problem-solving pro-cedure according to the criteria. Treatment as Usual
	 Beskrivelse: nefazodone monoterapi: Among the patients who received nefazodone, the initial dosewas 200 mg per day (100 mg twice a day) and was increased to300 mg per day during the second week. Thereafter, the dose wasincreased weekly in increments of 100 mg per day to a maximumof 600 mg per day, to maximize the efficacy of the drug

5

	withoutproducing intolerable side effects. To remain in the study, patientshad to be receiving a dose of at least 300 mg per day by week 3. Visits for medication were limited to 15 to 20 minutes.
Outcomes	Frafald/All cause discontinuation ● Outcome type: DichotomousOutcome
	Hospitalsindlæggelser ● Outcome type: DichotomousOutcome
	Hospitalsindlæggelser ● Outcome type: ContinuousOutcome
	Selvmordsadfærd ● Outcome type: DichotomousOutcome
	Arbejdsfastholdelse ● Outcome type: DichotomousOutcome
	Skadevirkninger (farmakologisk) ● Outcome type: AdverseEvent
	Funktionsevne (kritisk outcome) ● Outcome type: ContinuousOutcome
	Remissionsrate (kritisk outcome) ● Outcome type: DichotomousOutcome
	Livskvalitet (kritisk outcome) ● Outcome type: ContinuousOutcome
	 Outcome type: DichotomousOutcome Direction: Higher is better Data value: Endpoint Notes: A satisfactory therapeutic response was defined as a reduction in the HRSD score by at least 50 percent from baseline to week 10 and week 12, with a total score of 15 or less atthese times but of more than 8 at week 10, week 12, or both forthose who completed the study and at the time of
	departure forthose who did not complete the study. BDI (respons rate)
	Outcome type: DichotomousOutcome
Identification	Sponsorship source: Readers should know, however, that all but 1 (B.A.) ofthe 12 principal authors have had financial associations with Bris-tol-Myers Squibb — which also sponsored the study — and, inmost cases, with many other companies producing psychoactivepharmaceutical agents. Country: US Setting: outpatient Comments: Authors name: Keller et al, 2000
	Institution: Email: Address:

Notes	Jens Aaboe on 08/10/2015 07:05
	Outcomes
	Response rate for Ham-d: A satisfactory therapeutic response was defined as a reduction in the HRSD score by at least 50 percent from base line to week 10 and week 12, with a total score of 15 or less at these times but of more than 8 at week 10, week 12, or both for those who completed the study and at the time of departure for those who did not complete the study.
	Stine MøLler on 13/10/2015 23:08
	Population
	chronic major depressive disorder (at least two years' duration), a current major depressive disorder superimposed on a preexisting dysthymic disorder, or a recurrent major depressive disorder with incomplete remission between episodes in a patient with a current major depressive disorder and a total duration of continuous illness of at least two years

Risk of bias table

Bias	Authors' judgement	Support for judgement			
Sequence Generation	Low risk	Judgement Comment: "Central computerized randomization schedule, in a 1:1:1 ratio" "Central computerized randomization schedule, in a 1:1:1 ratio"			
Allocation concealment	Unclear risk	Judgement Comment: Not described			
Blinding of participants and personnel	High risk	Judgement Comment: Blinding not possible			
Blinding of outcome assessors	Low risk	Quote: "At all sites the rater was located at a separate physical location so that he or she could not see pa- tients arriving for or departing from treatment sessions."			
Incomplete outcome data	High risk	Judgement Comment: About 25% dropped out in each group.			
Selective outcome reporting	Low risk	Judgement Comment: Not detected			
Other sources of bias	High risk	Judgement Comment: Requirement for two-week drug free period prior to randomisation bias results against psychoterapy due to risk of confusion between treatment effect and alleviation of withdrawal symptoms. Also, previous non-responders were excluded, but we are not informed whether this predominantly led to exclusions for drug- or psychotherapy treated patients.			

Footnotes

References to studies

Included studies

Agosti 1997

Agosti, V.; Ocepek-Welikson, K.. The efficacy of imipramine and psychotherapy in early-onset chronic depression: a reanalysis of the National Institute of Mental health Treatment of Depression Collaborative Research Program. Journal of affective disorders 1997;43(3):181-186. [DOI: S0165-0327(97)01428-6 [pii]]

Keller 2000

Keller,M. B.; McCullough,J. P.; Klein,D. N.; Arnow,B.; Dunner,D. L.; Gelenberg,A. J.; Markowitz,J. C.; Nemeroff,C. B.; Russell,J. M.; Thase,M. E.; Trivedi,M. H.; Zajecka,J.. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. The New England journal of medicine 2000;342(20):1462-1470. [DOI: 10.1056/NEJM200005183422001 [doi]]

Data and analyses


1 Psychotherapy vs Treatment as Usual

Outcome or Subgroup	Studies	Participa nts	Statistical Method	Effect Estimate
1.1 Hospitalsindlæggelser	0	0	Mean Difference (IV, Fixed, 95% CI)	Not estimable
1.2 Funktionsevne (aktivitet og deltagelse)	0	0	Mean Difference (IV, Fixed, 95% CI)	Not estimable
1.3 Livskvalitet (kritisk outcome)	0	0	Mean Difference (IV, Fixed, 95% CI)	Not estimable
1.4 Funktionsevne (kritisk outcome)	0	0	Mean Difference (IV, Fixed, 95% CI)	Not estimable
1.5 Frafald/All cause discontinuation	2	504	Risk Ratio (IV, Fixed, 95% CI)	0.92 [0.67, 1.27]
1.5.1 Ved interventionens afslutning	2	504	Risk Ratio (IV, Fixed, 95% CI)	0.92 [0.67, 1.27]
1.6 Hospitalsindlæggelser	0		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.7 Selvmordsadfærd	0		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.8 Arbejdsfastholdelse	0		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.9 Remissionsrate (kritisk outcome)	1	454	Risk Ratio (IV, Fixed, 95% CI)	1.12 [0.84, 1.48]
1.9.1 Efter endt behandling	1	454	Risk Ratio (IV, Fixed, 95% CI)	1.12 [0.84, 1.48]

1.10 Ham-d (respons rate), IPT	1		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.10.1 Efter endt behandling, IPT som interventionsgruppe	1		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.11 BDI (respons rate), IPT	1		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.11.1 Efter endt behandling, IPT som interventionsgruppe	1		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.12 Ham-d (respons rate), CBT	1		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.12.1 Efter endt behandling, CBT som interventionsgruppe	1		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.13 BDI (respons rate), CBT	1		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.13.1 Efter endt behandling, CBT som interventionsgruppe	1		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.14 Ham-d (respons rate)	2	504	Risk Ratio (IV, Random, 95% CI)	0.96 [0.79, 1.16]
1.14.1 Efter endt behandling	2	504	Risk Ratio (IV, Random, 95% CI)	0.96 [0.79, 1.16]
1.15 BDI (respons rate)	0		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.16 Adverse events	1	454	Odds Ratio (M-H, Fixed, 95% CI)	0.08 [0.03, 0.28]

Figures

Figure 1 (Analysis 1.5)



Forest plot of comparison: 1 Psychotherapy vs Treatment as Usual, outcome: 1.5 Frafald/All cause discontinuation.

Figure 2 (Analysis 1.9)

	Psychothe	егару	Treatment as	Usual		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% C
1.9.1 Efter endt beha	ndling						
Keller 2000 Subtotal (95% CI)	72	228 228	64	226 226	100.0% 100.0 %	1.12 [0.84, 1.48] 1.12 [0.84, 1.48]	-
Total events	72		64				
Heterogeneity: Not ap	pplicable						
Test for overall effect	Z = 0.76 (P)	= 0.45)					
Total (95% CI)		228		226	100.0%	1.12 [0.84, 1.48]	•
Total events	72		64				
Heterogeneity: Not ap	pplicable						0.1 0.2 0.5 1 2
Test for overall effect					Favours medication Favou		
Test for subgroup dif	able				ravours modication ravou		

Risk of bias legend

- (A) Sequence Generation
- (B) Allocation concealment
- (C) Blinding of participants and personnel
- (D) Blinding of outcome assessors
- (E) Incomplete outcome data
- (F) Selective outcome reporting
- (G) Other sources of bias

Forest plot of comparison: 1 Psychotherapy vs Treatment as Usual, outcome: 1.9 Remissionsrate (kritisk outcome).

Figure 3 (Analysis 1.14)

	Psychotherapy		Psychotherapy Treatment as Usual		Usual	Risk Ratio		Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 9			
1.14.1 Efter endt beh	1.14.1 Efter endt behandling									
Agosti 1997	11	30	9	20	8.1%	0.81 [0.41, 1.60]				
Keller 2000	103	228	105	226	91.9%	0.97 [0.80, 1.19]				
Subtotal (95% CI)		258		246	100.0%	0.96 [0.79, 1.16]	-			
Total events	114		114							
Heterogeneity: Tau² =	: 0.00; Chi ² =	= 0.24, d	f = 1 (P = 0.62);	$I^2 = 0\%$						
Test for overall effect:	Z = 0.43 (P	= 0.67)								
T. 4. 1 (05% OB		050			400.00	0.0010.70.4.401				
Total (95% CI)		258		246	100.0%	0.96 [0.79, 1.16]				
Total events	114		114							
Heterogeneity: Tau ² =	= 0.00; Chi * =	= 0.24, d	f = 1 (P = 0.62);	$ ^2 = 0\%$			0.5 0.7 1			
Test for overall effect:	Z = 0.43 (P	= 0.67)					Favours medication Fav			
Test for subgroup diff	ferences: No	ot applic	able				ravours medication rav			

Risk of bias legend

- (A) Sequence Generation
- (B) Allocation concealment
- (C) Blinding of participants and personnel
- (D) Blinding of outcome assessors
- (E) Incomplete outcome data
- (F) Selective outcome reporting
- (G) Other sources of bias

Forest plot of comparison: 1 Psychotherapy vs Treatment as Usual, outcome: 1.14 Ham-d (respons rate).

Figure 4 (Analysis 1.16)

	Psychotherapy alone		Treatment as Usual		Odds Ratio		Odds
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fix
Keller 2000	3	228	31	226	100.0%	0.08 [0.03, 0.28]	_
Total (95% CI)		228		226	100.0%	0.08 [0.03, 0.28]	
Total events	3		31				
Heterogeneity: Not applicable							0.01 0.1
Test for overall effect: Z = 4.05 (P < 0.0001)							Favours psychotherapy

Risk of bias legend

- (A) Sequence Generation
- (B) Allocation concealment
- (C) Blinding of participants and personnel
- (D) Blinding of outcome assessors
- (E) Incomplete outcome data
- (F) Selective outcome reporting
- (G) Other sources of bias

Forest plot of comparison: 1 Psychotherapy vs Treatment as Usual, outcome: 1.16 Adverse events.